Background {#Sec1}
==========

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y~12~ antagonist represents the standard of care in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary interventions (PCI) \[[@CR1]\]. However, a concerning issue is that wide inter-individual variability exists among P2Y~12~ antagonist, especially clopidogrel \[[@CR2]--[@CR4]\]. The incidence of high on-treatment platelet reactivity (HPR) can be as high as in one-third of patients treated with clopidogrel, and HPR is present even in those receiving the more potent P2Y~12~ antagonists ticagrelor and prasugrel \[[@CR5]\]. Numerous studies have demonstrated that HPR is associated with increased cardiovascular death and thrombotic events \[[@CR6], [@CR7]\]. Several small clinical studies have shown that increasing the dose of clopidogrel or switching to a more potent P2Y~12~ receptor inhibitor in patients with HPR can significantly reduce the incidence of major adverse cardiac events (MACE) \[[@CR8]--[@CR10]\]. However, large randomized trials failed to demonstrate similar improvements in clinical outcomes with a tailored antiplatelet therapy based on platelet function monitoring \[[@CR11]--[@CR14]\]. Therefore, though some studies found platelet reactivity-guided antiplatelet therapy to be beneficial in certain clinical endpoints like bleeding and stent thrombosis \[[@CR15]\], the usefulness of tailored antiplatelet therapy during PCI is still controversial. In the present study, we performed meta-analysis on previous studies to evaluate the clinical efficacy and safety of individualized intensification of antiplatelet therapy with P2Y~12~ inhibitors versus standard dose clopidogrel on the basis of platelet function testing(PFT) in patients undergoing PCI.

Methods {#Sec2}
=======

PubMed, MEDLINE and ClinicalTrials were searched for clinical studies published between January 2005 and September 2016. The key words we used included the following terms: 'platelet function', 'platelet reactivity', 'platelet aggregation', 'platelet aggregometry', 'antiplatelet resistance','high on treatment platelet reactivity','P2Y~12~-ADP receptor inhibitor', 'clopidogrel', 'prasugrel', 'ticagrelor' and 'percutaneous coronary intervention'. In addition, references of relevant studies and reviews, editorials, and letters, together with related conference abstracts were also searched.

The main criteria for inclusion in this analysis were trials that compared clinical efficacy and/or safety of an intensified antiplatelet therapy with that of standard-dose clopidogrel therapy on the basis of platelet reactivity testing in patients undergoing PCI. Studies without platelet function testing were excluded. Similarly, studies that compared only the pharmacological efficacy of a platelet function-guided anti-platelet therapy were also excluded. Moreover, studies in which platelet inhibitor other than P2Y~12~ inhibitors were used were excluded.

According to international consensus and previous studies \[[@CR16], [@CR17]\],the accepted ADP-specific platelet function devices were: (a) VerifyNow P2Y~12~ assay, (b) Multiplate analyzer with ADP test, (c) Flow cytometric assessment of vasodilator stimulated phosphoprotein (VASP) phosphorylation index, and (d) Conventional light transmission aggregometry (LTA).

The efficacy endpoints of the analysis included: (a) Major adverse cardiovascular events (MACE), (b) Cardiovascular death, (c) Definite/probable ST, (d) Myocardial infarction (MI), (e) Stroke and (f) Target vessel revascularization (TVR). All of them were defined according to the study definition. In particular, MACE was primarily defined as a composite of cardiovascular death, myocardial infarction and definite/probable stent thrombosis, though a few studies also included endpoint of stroke or transient ischemic attack (TIA). The main safety endpoint was major bleeding and major or minor bleeding events, which were defined according to the study definition,including BARC, TIMI, GUSTO and STEEPLE \[[@CR18]--[@CR21]\]. The net clinical end point was defined as a composite of MACE and major bleeding.

Two investigators independently assessed reports for eligibility on the title and/or at abstract level, with divergences resolved with a third reviewer; studies that met inclusion criteria were selected for further analysis. The risk of bias was evaluated by the same two reviewer authors, in accordance with The Cochrane Collaboration methods \[[@CR22]\].

Meta-analysis was performed using the Review Manager 5.3 and STATA 14 statistical software. Reported event frequencies were used to calculate risk ratios (RR) with 95% confidence intervals (CI). Heterogeneity of the trial results was quantified with the Chi^2^ heterogeneity statistic, with inconsistency assessed by means of I^2^. Results were reported as the *p* value of the Chi^2^ test (*p* \< 0.05 for heterogeneous results) and percentage of the I^2^. Interpretation of the latter was made by assigning attributes of low, moderate, and high in case of 0--25%, 50--75% and more than 75%, respectively. We used a random-effects or a fixed-effect model based on degree of heterogeneity. The random-effects model results in wider confidence intervals and provides more conservative and robust results, and it was used when I^2^ \> 50%. Subgroup analyses were performed according to strategies to overcome HPR, intervention duration, follow-up duration and method of platelet function testing. Analysis of variance(ANOVA) were further carried out between different subgroups. To determine the impact of baseline risks and study characteristics on the MACE and net clinical benefit, meta-regression analyses were performed with STATA 14 software. To study the relevance of publication bias, funnel plots were constructed plotting the trial results against their precision. Begg's regression intercept was used to assess asymmetry of these funnel plots. Only composite clinical endpoints were used from the meta-analysis. The Duval and Tweedie's "Trim and Fill" method was used to impute 'hypothetical' missing studies and to calculate adjusted versus observed RRs.

Results {#Sec3}
=======

Through searching with aforementioned key words, 3466 reports were retrieved, of which 2239 relevant publications were identified at the abstract and title level. Full text assessment was performed in 32 trials. By applying the inclusion and exclusion criteria, thirteen studies involving 7290 (range: 60--2440) patients were qualified for the analysis (Fig. [1](#Fig1){ref-type="fig"}). A summary table of review authors' judgements for each risk of bias item for each study was shown in Fig. [2](#Fig2){ref-type="fig"}. The detailed characteristics of the included studies are shown in Table [1](#Tab1){ref-type="table"}. Studies vary according to publication year, risk profiles of the recruited patients, platelet function assay used, definition of HPR, intensified antiplatelet strategy applied and clinical endpoints. All studies used P2Y~12~ antagonist for intensified antiplatelet regime: two studies administered repeated loading dose of 600 mg clopidogrel \[[@CR8], [@CR9]\]; seven studies increased maintenance dose of clopidogrel \[[@CR11], [@CR23]--[@CR28]\]; two studies used repeated loading dose of 600 mg clopidogrel combined with increased maintenance dose of clopidogrel or prasugrel \[[@CR29], [@CR30]\]; another two studies used prasugrel for loading and maintenance \[[@CR13], [@CR14]\].Fig. 1Flowchart of study selection Fig. 2Summary table of review authors' judgements for each risk of bias item for each study Table 1Study characteristicsAuthorAcronymDateBlindingPatient no. (tailored/control)Platelet function assayHPR cut-offAleil2008No31/62VASPVASP-PRI \> 69%Bonello2008No78/84VASPVASP-PRI \> 50%Bonello2009No215/214VASPVASP-PRI \> 50%AradiDOSER2010Yes36/38LTA, 5 μM ADP\>34%AGGmaxPriceGRAVITAS2010No1109/1105VerifyNow,P2Y12\>230PRUAriEFFICIENT2011Yes47/47VerifyNow P2Y12\<40%inhibitionHazarbasanov2011No97/95VerifyNow P2Y12\>208PRUTousek2011No30/30VerifyNow P2Y12\>240PRUTrenkTRIGGER-PCI2011Yes212/211VerifyNow P2Y12\>208PRUWang2011No150/156VASPVASP-PRI \> 50%ColletARCTIC2012No1213/1227VerifyNow,P2Y12\>235PRUSamardzic2014No43/44MEA\>46 UCaylaANTARCTIC2016No435/442VerifyNow,P2Y12\>208PRUAuthorClinical settingModified treatmentIntervention durationFollow-upAleilScheduled for elective coronary stenting150 mg MD clopidogrel2 weeks1 monthBonelloStable angina:52% NSTEMI:48% STEMI: 0%Repeated 600 mg clopidogrel LDOne week30 daysBonelloStable angina:48% NSTEMI:52% STEMI: 0%Repeated 600 mg clopidogrel LDOne week30 daysAradiStable angina:100%600 mg LD +150 mg MD clopidogrel1 month12 monthsPriceStable angina:60% NSTEMI:10.1% STEMI: 0.4%600 mg LD +150 mg MD clopidogrel6 months6 monthsAriStable angina:100%150 mg MD clopidogrel1 month6 monthsHazarbasanovStable angina:43% NSTEMI:33% STEMI: 24%600 mg LD +150 mg clopidogrel1 month6 monthsTousekStable angina:23% NSTEMI:34% STEMI: 43%clopidogrel starting at 150 mg/day with further dose increase1 month6 monthsTrenkStable angina:100%60 mg LD +10 mg MD Prasugrel6 months6 monthsWangStable angina:80% NSTEMI:20% STEMI: 0%increase in clopidogrel MD up to 375 mg11 months1 yearColletScheduled for elective coronary stentingRepeated 600 mg clopidogrel LD + 150 mg MD clopidogrel/10 mg MD Prasugrel12 months12 monthsSamardzicStable angina:16% NSTEMI:23%STEMI:60%up to clopidogrel 600 mg × 2 + (75-300 mg MD)12 months12 monthsCaylaStable angina:18% NSTEMI:48%STEMI:34%5--10 mg MD Prasugrel12 months12 months*Abbreviations ACS* acute coronary syndrome, *CV* cardiovascular, *HTPR* high on-treatment platelet reactivity, *LD* loading dose, *MD* maintenance dose, *MI* myocardial infarction, *STEMI* ST-segment elevation myocardial infarction, *NSTEMI* non-ST segment elevation myocardial infarction, *ST* stent thrombosis, *TVR* target vessel revascularization, *MACE* major adverse cardiovascular events *RCT* randomized, controlled trial

Based on the pooled results, the intensified therapy was associated with a significant reduction in major adverse cardiovascular events (MACE) (RR: 0.55, 95% CI: 0.36--0.84, *p* = 0.005; Fig. [3](#Fig3){ref-type="fig"}). Moreover, intensified antiplatelet strategy guided by platelet function testing reduced rate of cardiovascular death (RR: 0.60, 95% CI: 0.38--0.96, *p* = 0.03), definite/probable stent thrombosis (RR: 0.58, 95% CI: 0.36--0.93, *p* = 0.02) and target vessel revascularization (TVR) (RR: 0.33, 95% CI: 0.14--0.76, *p* = 0.009) (Figs. [4a-c](#Fig4){ref-type="fig"}). On the other hand, there was no difference in incidence of death from any cause (RR: 0.95, 95% CI: 0.65--1.39, *p* = 0.81) or myocardial infarction (RR: 1.02, 95% CI: 0.91--1.15, *p* = 0.74) between platelet function-guided intensified antiplatelet strategy with standard maintenance dose of clopidogrel therapy (Fig. [4d-e](#Fig4){ref-type="fig"}).Fig. 3Forest plot for incidence of major adverse cardiovascular events. Risk ratio for individual studies (*squares*) and meta-analysis (*diamonds*) and 95% CI (*horizontal lines*) are presented Fig. 4Forest plot for incidence of cardiovascular death, **a** stent thrombosis **b**, target vessel revascularization, **c** death **d** and myocardial infarction **e**. Risk ratio for individual studies (squares) and meta-analysis (diamonds) and 95% CI (horizontal lines) are presented

No difference in the rate of major bleeding events (RR: 0.75, 95% CI: 0.54--1.03, *p* = 0.08) or major or minor bleeding events (RR: 1.04, 95% CI: 0.88--1.23, *p* = 0.67) was observed between the two therapeutic groups (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Forest plot for incidence of major bleeding **a** and major or minor bleeding **b**. Risk ratio for individual studies (squares) and meta-analysis (diamonds) and 95% CI (horizontal lines) are presented

The net clinical benefit, consisting of both thrombotic and bleeding events, was also superior in intensified therapy (RR: 0.67, 95% CI: 0.49--0.93, *p* = 0.02) (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Forest plot for incidence of net clinical benefit. Risk ratio for individual studies (squares) and meta-analysis (diamonds) and 95% CI (horizontal lines) are presented

Subgroup analyses were performed. According to strategies to overcome HPR (repeated clopidogrel loading, increased clopidogrel maintenance dose or switching to prasugrel), pooled results showed that repeated loading or increased maintenance dose of clopidogrel significantly reduced the incidence of MACE without increasing major bleeding events, favoring a net clinical benefit. However, switching to prasugrel was similar with standard therapy in MACE, major bleeding and net clinical benefit. Pooled results from trials with intervention duration of 1 month or less and follow-up time of 1 month showed that intensified antiplatelet strategy significantly decreased the MACE, cardiovascular death and net clinical events. Results from studies using VASP showed that intensified therapy was associated with less incidence of MACE, cardiovascular death and net clinical events (Table [2](#Tab2){ref-type="table"}). ANOVA analyses were also performed between subgroups according to strategies to overcome HPR, intervention duration, follow-up duration and platelet function testing, showing that differences across subgroups in MACE and net clinical events are significant (Table [2](#Tab2){ref-type="table"}). What's more, pooled result from studies only included patients with stable coronary artery disease showed that intensified therapy decreased the incidence of MACE (RR: 0.23, 95%CI: 0.09--0.60, *p* = 0.002 (Additional file [1](#MOESM1){ref-type="media"}).Table 2Subgroup analysisMACECardiovascular deathMajor bleedingNet clinical eventsRR(95% CI)I^2^ (%)*p*RR(95% CI)I^2^ (%)*p*RR(95% CI)I^2^ (%)*p*RR(95% CI)I^2^ (%)*pStrategies to overcome HPR*0.020.260.60\<0.001Repeated LD0.06(0.01--0.29)0\<0.0010.15(0.02--1.18)00.071.02(0.21--5.02)00.980.14(0.05--0.38)0\<0.001Increased MD0.56(0.39--0.96)660.0030.41(0.20--0.84)00.010.69(0.38--1.25)00.220.59(0.44--0.81)100.001Switch to prasugrel0.77(0.28--2.15)490.621.01(0.49--2.11)50.971.00(0.81--1.24)01.00*Intervention duration*\<0.0010.060.26\<0.001≤1 month0.16(0.07--0.37)0\<0.0010.17(0.04--0.75)00.021.51(0.43--5.34)00.520.21(0.11--0.42)0\<0.001\>1 month0.81(0.58--1.14)650.230.75(0.45--1.25)60.270.71(0.51--0.99)00.050.93(0.75--1.14)540.47*Follow up duration*0.030.110.91\<0.0011 month0.09(0.02--0.40)00.0010.15(0.02--1.18)00.071.02(0.21--5.02)00.980.15(0.06--0.38)0\<0.0016 months0.48(0.21--1.11)380.090.30(0.09--1.00)00.050.77(0.44--1.36)110.380.72(0.49--1.08)20.1112 months0.73(0.46--1.14)750.160.84(0.49--1.15)00.530.72(0.49--1.08)00.110.93(0.72--1.21)710.60*Platelet function device*0.050.270.72\<0.001VerifyNow0.94(0.70--1.27)370.690.69(0.37--1.32)390.260.76(0.54--1.05)00.100.98(0.82--1.16)260.79VASP0.20(0.05--0.91)580.040.38(0.16--0.89)00.031.02(0.21--5.02)00.980.27(0.12--0.59)380.001

To evaluate the impact of baseline clinical risks and study characteristics on the MACE and net clinical benefit of the individualized therapy, we performed meta-regression for different variables, including percentage of ACS patients, study size, patient age, cut-off value for HPR, follow-up time (≤1 months or \>1 months) and intervention duration (1 month, 6 months or 12 months) (Table [3](#Tab3){ref-type="table"}). Our analysis showed that study size and intervention duration were significantly associated MACE, and the above two factors as well as follow-up time were associated with net clinical benefit, suggesting the heterogeneity in clinical efficacy were partially explained by these factors .Table 3Meta-regression analyses for MACE and net clinical benefitMACENet clinical benefit*p*Adj-R^2^ (%)I^2^ (%)Tau^2^*p*Adj-R^2^ (%)I^2^ (%)Tau^2^Percentage of ACS0.0287.5954.650.39790.211054.620.4356Age0.229070.270.4560.1958.9950.750.2937Verifynow cutoff value0.566022.1400.864020.590.1935Study size0.00544.1346.130.24060.0324.9166.220.3069Follow up0.07722.4560.230.31810.02261.7240.970.1219Intervention duration0.00576.0636.870.098180.00686.6918.980.04239

To check for the possibility of a publication bias, we used Begg's test and found no publication bias in cardiovascular death (*p* = 0.536), definite/probable ST (*p* = 0.108), myocardial infarction (*p* = 0.386), MACE (*p* = 0.583), major bleeding (*p* = 0.175) and net clinical benefits (*p* = 0.350). Furthermore, sensitivity analysis by Trim and Fill method showed that the pooled results of MACE and net clinical benefits were reliable.

Discussion {#Sec4}
==========

The results our meta-analysis showed that in patients undergoing PCI with HPR, a strategy of individualized intensification of dual antiplatelet therapy reduces adverse cardiovascular events, including cardiovascular death, stent thrombosis and target vessel revascularization, without increasing hemorrhagic complications.

Dual antiplatelet therapy with aspirin and P2Y~12~ antagonists has become the standard therapy for preventing adverse cardiovascular events after PCI. However, considerable inter-individual variability exists among patients receiving clopidogrel. Many observational studies have established HPR as the risk factor for ischemic events after PCI, but whether modifying HPR with intensified antiplatelet regime can improve cardiovascular outcome is still controversial. AHA/ACC guidelines of PCI recommend that in patients at high risk of stent thrombosis, platelet aggregation test may be applied, and that if platelet inhibition is inadequate, clopidogrel dose may be increased \[[@CR31], [@CR32]\]. Since the prognostic value of bleeding complications is equally important as ischemic events, a personalized approach to tailor the antiplatelet therapy for patients with variable on-treatment platelet reactivity is an attractive strategy. Though small clinical trials have demonstrated that increasing the dose of clopidogrel in patients with HPR can reduce the incidence of major adverse cardiac events, some large randomized trials failed to demonstrate an improvements in clinical outcomes with a tailored anti-platelet therapy based on platelet-function monitoring \[[@CR11], [@CR13], [@CR29]\]. The small number of events in low risk patients included in these trials might be accountable for negative results. Moreover, poor responsiveness is likely due to multifactorial reasons, including clinical, cellular and genetic factors, with gene polymorphisms emerging as one of the major determinants of clopidogrel response \[[@CR33]--[@CR35]\]. Different mutations may lead to discrepant gene function, therefore resulting in poor to no clopidogrel response. Intensified anti-platelet regime used in these trials might overcome certain types of mutations, but could not achieve sufficient platelet inhibition in patients with specific genotype. What's more, recent studies demonstrated that the magnitude of the association between HPR on clopidogrel treatment and incidence of MACE is strongly dependent on the level of patients' cardiovascular risk \[[@CR36]\].

Previously published meta-analysis on intensified antiplatelet therapy on the basis of platelet reactivity testing suggested that in patients undergoing PCI who have HPR, more potent antiplatelet regime reduced the rate of thrombotic events without increasing the risk for bleeding events \[[@CR37], [@CR38]\]. But these studies synthesized different classes of antiplatelet agents, including peri-procedural use of glycoprotein IIb/IIIa receptor inhibitors (GPIs). Our study focused on dual antiplatelet therapy with aspirin and P2Y~12~ antagonists only, since we believe with broader application of newer P2Y~12~ inhibitors, procedural use of GPI would be gradually decreasing. Our results clearly showed that individualized intensification of dual anti-platelet therapy reduced adverse cardiovascular events,which might mainly derive from the decreasing of cardiovascular death, stent thrombosis and target vessel revascularization, leading to net clinical benefit.

From our subgroup analysis, we found strategy of overcoming HPR had a major impact on clinical efficacy. While repeated loading or increased maintenance dose of clopidogrel significantly reduced incidence of MACE and favored net clinical benefit, it is intriguing to find the newer P2Y~12~ inhibitors prasugrel did not. Though the reason remained unknown, possible explanations are: 1) number of studies that used prasugrel (only TRIGGER-PCI and ANTARCTIC study) is far less than those used higher doses of clopidogrel, potentially biasing the result; 2) TRIGGER-PCI study included patients at low ischemic rate, possibly masking the benefit of prasugrel; 3) ANTARCTIC study only enrolled patients of 75 years or older, its failure to demonstrate the benefit of prasugrel is limited to this sub-population. Whether PFT-based prasugrel dosing could reduce ischemic event in a broader patient population with higher risks needs further investigation. It would also be interesting test another new P2Y12 inhibitor, ticagrelor. Our analysis and meta-regression analysis also showed studies with short intervention duration (≤1 month) and follow-up time (1 month) were more beneficial than those with longer intervention or follow-up duration in the endpoints of MACE, cardiovascular death and net clinical events. It seems reasonable that the PFT-guided anti-platelet therapy is prone to reduce shorter-term cardiovascular events, since platelet function testing are mostly performed peri-procedurally and reflects peri-procedural thrombotic burden. It is also interesting from our analysis that considering studies using only Verifynow, such strategy did not reduce any cardiovascular outcomes, as opposed to VASP. One reason is that studies using Verifynow adopted different thresholds for HPR, ranging from \>208 PRU to \>240 PRU. Also possible is that VerifyNow-P2Y12 cartridge might be influenced by many factors such as time between process, platelet count, hematocrit and etc. However, whether VASP is indeed better than VerifyNow in guiding individualized DAPT needs further study.

Previous studies reported inconsistent results in the relationship between HPR and bleeding. Sibbing et al. showed that patients with and without HPR had similar incidence of major and minor bleeding \[[@CR4]\]. However, ADAPT-DES trial found that HPR was inversely related to bleeding events \[[@CR39]\]. Evidence is still lacking in applying PFT to estimate bleeding risk. In our study, we found no difference in bleeding events between two groups, indicating only the safety of PFT-based intensified antiplatelet therapy.

Newly developed P2Y~12~ inhibitors prasugrel and ticagrelor are more potent and have a faster onset of action than clopidogrel, making them particularly attractive for patients undergoing PCI. In ACS patients exhibiting HPR on clopidogrel after PCI, both ticagrelor and prasugrel provide effective and sufficient platelet inhibition \[[@CR40]\]. Studies have demonstrated that in patients with HPR, switching to prasugrel achieved adequate platelet inhibition and reduced thrombotic events \[[@CR41], [@CR42]\]. With increasing usage of newer P2Y~12~ inhibitors for coronary intervention, it may seem less necessary to concern about platelet resistance. However, there are still several issues unsettled. A proportion of patients treated with new P2Y~12~ inhibitors still display HPR, particularly during acute phase of myocardial infarction, putting forward an issue of how to deal with these non-responders. More importantly, new P2Y~12~ inhibitors carry an increased bleeding risk, so it would be challenging to tailor these agents with a balance between ischemic events and hemorrhagic complications. Platelet function testing may help sort out patients with benefit/risk ratio favorable for more potent anti-platelet therapy. As indicated in our analysis, the individualized approach based on PFT can improve net clinical benefit and should be considered to guide anti-platelet regime in future practice. Still, an appropriate defining of therapeutic window based on different methods of PFT needs further investigation to optimize intensified anti-platelet therapy.

It is noteworthy that our study included target vessel revascularization in the endpoint. The rationale of incorporating TVR in our analysis was that several studies have demonstrated a significant increase in revascularization rate in patients with HPR \[[@CR43], [@CR44]\]. More importantly, though still controversial, the notion that intensified antiplatelet therapy may have an inhibitory effect upon in-stent restenosis has been supported by some studies. For example, the DECLARE study series showed that cilostazol-based triple antiplatelet therapy could reduce angiographic restenosis and target lesion revascularization \[[@CR45], [@CR46]\]. Experimental research also indicated that the more potent ticagrelor could effectively inhibit neointima formation and potentially reduce restenosis \[[@CR47]\]. Furthermore, the recent TRANSLATE-ACS study showed that switching clopidogrel to prasugrel led a significant decrease in unplanned revascularization rate \[[@CR44]\]. In agreement with above findings, our pooled result also revealed association between intensified P2Y12 inhibition and reduction of TVR. However, since current level of evidence is still low, further study is needed to confirm whether more potent anti-platelet regime would decrease in-stent restenosis and incidence of TVR.

Our study has several limitations that should be taken into account. First, since there is no general agreement on standard definition of platelet resistance, studies included in our analysis used different definitions of platelet resistance or non-responsiveness. Defining HPR also varies according to the method of PFT, though there is an adequate correlation between different tests \[[@CR48]\]. Since HPR cutoff values reported in many studies are associated with high negative predictive values and low positive predictive values, it may have an impact on the pooled results. Second, while most studies defined MACE as composite of cardiovascular death, myocardial infarction and definite/probable stent thrombosis, three studies included stroke/TIA in MACE as well. However, due to low incidence of stroke/TIA in these studies, the difference in the definition of MACE across studies is unlikely to affect our pooled results. Third, trials included in our study used different strategies to overcome HPR, so the extent of platelet inhibition is not same. Tailored therapy like doubling the dose of clopidogrel may still be insufficient to repress platelet activity. Forth, risk profile of patients included in our study was different. Patients in high risk group tend to have higher cardiovascular events, which may also affect the pooled results. What's more, a small part of patients with low on-treatment reactivity were mixed in platelet function monitoring group in some studies, such as ARCTIC and ANTARCTIC trials. Such design may partly neutralize the benefit of tailored therapy, and have some affect in the pooled results.

Conclusion {#Sec5}
==========

In conclusion, the present meta-analysis from RCTs suggests that in patients undergoing PCI who have HPR based on platelet function testing, intensified dual anti-platelet therapy reduces the incidence of thrombotic events without increasing the risk of major bleeding compared with standard clopidogrel therapy.
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